创新药板块回调，创新药ETF国泰（517110）跌近3.0%，机构称行业估值低位或存修复空间

Group 1 - The core viewpoint is that the pharmaceutical and biotechnology industry is currently focused on innovative drugs and AI healthcare, with the latter showing strong performance due to the launch of Ant Group's AI health application AQ [1] - The chemical pharmaceutical sub-sector has the highest monthly return at 4.59%, outperforming the CSI 300 index which has a return of 2.45%. However, its weekly return ranks sixth with a change of 0.71%, compared to the CSI 300's -1.24% [1] - The valuation of the pharmaceutical and biotechnology industry is at a historically low level, with a current PE (TTM) of 27.69 times, compared to a 5-year historical average PE of 30.91 times [1] Group 2 - The Guotai Innovation Drug ETF tracks the SHS Innovation Drug (RMB) Index, which focuses on listed companies involved in the research, production, and sales of innovative drugs across the Shanghai, Shenzhen, and Hong Kong markets [1] - The index covers sectors such as biomedicine and chemical pharmaceuticals, emphasizing companies with core innovation capabilities and high growth potential, reflecting the overall performance of the innovative drug industry chain [1] - Investors without stock accounts can consider the Guotai CSI Hong Kong-Shenzhen Innovation Drug Industry ETF Initiated Link A (014117) and Link C (014118) [1]